ALPN
Income statement / Annual
Last year (2023), Alpine Immune Sciences, Inc.'s total revenue was $58.88 M,
an increase of 95.84% from the previous year.
In 2023, Alpine Immune Sciences, Inc.'s net income was -$32.18 M.
See Alpine Immune Sciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$58.88 M |
$30.06 M |
$23.44 M |
$9.34 M |
$1.74 M |
$705,000.00 |
$1.73 M |
$2.95 M |
$492,000.00 |
$0.00 |
| Cost of Revenue |
$80.90 M
|
$597,000.00
|
$620,000.00
|
$27.19 M
|
$35.85 M
|
$28.97 M
|
$10.63 M
|
$143,000.00
|
$66,000.00
|
$0.00
|
| Gross Profit |
-$22.03 M
|
$29.47 M
|
$22.82 M
|
-$17.85 M
|
-$34.11 M
|
-$28.27 M
|
-$8.90 M
|
$2.81 M
|
$426,000.00
|
$0.00
|
| Gross Profit Ratio |
-0.37
|
0.98
|
0.97
|
-1.91
|
-19.6
|
-40.09
|
-5.14
|
0.95
|
0.87
|
0
|
| Research and Development Expenses |
$80.90 M
|
$70.24 M
|
$58.74 M
|
$27.19 M
|
$35.85 M
|
$28.97 M
|
$10.63 M
|
$23.32 M
|
$16.05 M
|
$12.20 M
|
| General & Administrative Expenses |
$22.22 M
|
$17.97 M
|
$14.56 M
|
$10.90 M
|
$9.47 M
|
$8.36 M
|
$6.08 M
|
$8.59 M
|
$6.84 M
|
$2.29 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.22 M
|
$17.97 M
|
$14.56 M
|
$10.90 M
|
$9.47 M
|
$8.36 M
|
$6.08 M
|
$8.59 M
|
$6.84 M
|
$2.29 M
|
| Other Expenses |
$0.00
|
-$97,000.00
|
-$4,000.00
|
$1.33 M
|
$812,000.00
|
$1.20 M
|
$0.00
|
$0.00
|
$80,000.00
|
$296,343.00
|
| Operating Expenses |
$103.13 M
|
$88.21 M
|
$73.30 M
|
$38.08 M
|
$45.31 M
|
$37.33 M
|
$16.71 M
|
$31.90 M
|
$22.90 M
|
$14.49 M
|
| Cost And Expenses |
$103.13 M
|
$88.21 M
|
$73.30 M
|
$38.08 M
|
$45.31 M
|
$37.33 M
|
$16.71 M
|
$31.90 M
|
$22.90 M
|
$14.49 M
|
| Interest Income |
$11.85 M
|
$3.29 M
|
$259,000.00
|
$245,000.00
|
$1.25 M
|
$1.30 M
|
$542,000.00
|
$439,000.00
|
$80,000.00
|
$0.00
|
| Interest Expense |
$98,000.00
|
$476,000.00
|
$816,000.00
|
$775,000.00
|
$338,000.00
|
$319,000.00
|
$152,000.00
|
$0.00
|
$0.00
|
$845,099.00
|
| Depreciation & Amortization |
$576,000.00
|
$3.19 M
|
$255,000.00
|
$1.58 M
|
$2.06 M
|
$388,000.00
|
$241,000.00
|
$143,000.00
|
$66,000.00
|
$86,440.00
|
| EBITDA |
-$43.67 M |
-$54.96 M |
-$49.60 M |
-$27.17 M |
-$41.51 M |
-$35.33 M |
-$14.19 M |
-$31.90 M |
-$22.90 M |
-$14.10 M |
| EBITDA Ratio |
-0.74
|
-1.83
|
-2.12
|
-2.91
|
-23.86
|
-50.11
|
-8.2
|
-10.81
|
-46.54
|
0
|
| Operating Income Ratio |
-0.75
|
-1.93
|
-2.13
|
-3.08
|
-25.04
|
-53.66
|
-8.65
|
-10.81
|
-46.54
|
0
|
| Total Other Income/Expenses Net |
$12.17 M
|
$2.72 M
|
-$561,000.00
|
$803,000.00
|
$1.72 M
|
$977,000.00
|
$6.99 M
|
$439,000.00
|
$80,000.00
|
-$548,756.00
|
| Income Before Tax |
-$32.08 M
|
-$55.43 M
|
-$50.42 M
|
-$27.95 M
|
-$41.85 M
|
-$36.85 M
|
-$7.98 M
|
-$31.46 M
|
-$22.82 M
|
-$15.04 M
|
| Income Before Tax Ratio |
-0.54
|
-1.84
|
-2.15
|
-2.99
|
-24.05
|
-52.27
|
-4.61
|
-10.67
|
-46.38
|
0
|
| Income Tax Expense |
$103,000.00
|
$2.33 M
|
-$87,000.00
|
-$6,000.00
|
$682,000.00
|
-$366,000.00
|
-$200,000.00
|
-$143,000.00
|
-$66,000.00
|
$1.14 M
|
| Net Income |
-$32.18 M
|
-$57.76 M
|
-$50.33 M
|
-$27.94 M
|
-$42.53 M
|
-$36.49 M
|
-$7.78 M
|
-$31.46 M
|
-$22.82 M
|
-$15.04 M
|
| Net Income Ratio |
-0.55
|
-1.92
|
-2.15
|
-2.99
|
-24.44
|
-51.75
|
-4.5
|
-10.67
|
-46.38
|
0
|
| EPS |
-0.64 |
-1.73 |
-1.98 |
-1.34 |
-2.32 |
-2.63 |
-1.2 |
-8.12 |
-9.74 |
-6.59 |
| EPS Diluted |
-0.64 |
-1.73 |
-1.98 |
-1.34 |
-2.32 |
-2.63 |
-1.2 |
-8.12 |
-9.74 |
-6.59 |
| Weighted Average Shares Out |
$50.00 M
|
$33.44 M
|
$25.48 M
|
$20.83 M
|
$18.36 M
|
$13.85 M
|
$6.48 M
|
$3.87 M
|
$2.34 M
|
$2.28 M
|
| Weighted Average Shares Out Diluted |
$50.00 M
|
$33.44 M
|
$25.48 M
|
$20.83 M
|
$18.36 M
|
$13.85 M
|
$6.48 M
|
$3.87 M
|
$2.34 M
|
$2.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
